Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Septorhinoplasty Post-operative Pain Control With SPG Nerve Block

Phase 4

Recruiting

Conditions: Deviated Nasal Septum

Interventions: Drug: Ropivacaine
Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2022-12-28

Last Posted Date: 2024-05-30

Lead Sponsor: University of Florida

Target Recruit Count: 120

Registration Number: NCT05667324

Locations: 🇺🇸
UF Health of University of Florida, Gainesville, Florida, United States

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Phase 2

Recruiting

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Other: autologous stem cell transplant

First Posted Date: 2022-12-27

Last Posted Date: 2024-12-11

Lead Sponsor: University Hopsital Schleswig Holstein Campus Lübeck

Target Recruit Count: 100

Registration Number: NCT05665140

Locations: 🇩🇪
Heloisklinikum Berlin Buch GmbH, Berlin, Germany
🇩🇪
Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin, Bielefeld, Germany
🇩🇪
Universitätsklinikum Münster, Münster, Germany

and more 3 locations

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Dexamethasone
Drug: Montelukast
Drug: Methotrexate
Drug: Amivantamab
Drug: Lazertinib

First Posted Date: 2022-12-23

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 73

Registration Number: NCT05663866

Locations: 🇫🇷
Hopital Europeen Georges-Pompidou, Paris, France
🇫🇷
CHU Rouen Hopital Charles Nicolle, Rouen, France
🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

and more 33 locations

HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent

Interventions: Drug: Trametinib
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Intrathecal chemotherapy

First Posted Date: 2022-12-21

Last Posted Date: 2024-11-11

Lead Sponsor: Princess Maxima Center for Pediatric Oncology

Target Recruit Count: 26

Registration Number: NCT05658640

Locations: 🇦🇹
St. Anna Kinderspital, Vienna, Austria
🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇩🇰
Rigshospitalet Copenhagen, Copenhagen, Denmark

and more 33 locations

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Vincristine
Drug: Daunorubicin
Drug: Cyclophosphamide
Drug: Pegaspargase
Drug: Prednisone
Drug: Cytarabine
Drug: 6-mercaptopurine
Drug: Dexamethasone
Drug: Methotrexate
Drug: Venetoclax

First Posted Date: 2022-12-21

Last Posted Date: 2023-03-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 100

Registration Number: NCT05660473

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Distal Radius Steroid

Phase 1

Terminated

Conditions: Fractures, Bone
Radius Fracture Distal
Fractures, Closed

Interventions: Other: Standard of Care
Drug: Dexamethasone
Drug: Methylprednisolone

First Posted Date: 2022-12-19

Last Posted Date: 2024-01-23

Lead Sponsor: Indiana Hand to Shoulder Center

Target Recruit Count: 30

Registration Number: NCT05655130

Locations: 🇺🇸
Indiana Hand to Shoulder Center, Indianapolis, Indiana, United States

101-PGC-005 for the Treatment of COVID-19

Phase 2

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: 101-PGC-005
Drug: Dexamethasone

First Posted Date: 2022-12-19

Last Posted Date: 2023-05-30

Lead Sponsor: 101 Therapeutics

Target Recruit Count: 62

Registration Number: NCT05656521

Locations: 🇮🇳
Sangvi Multispeciality Hospital, Pune, Maharashtra, India
🇮🇳
Victoria Hospital Bangalore, Bangalore, Karnataka, India
🇮🇳
Santosh Medical College and Hospital, Ghāziābād, Uttar Pradesh, India

and more 2 locations